TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
38 hedge funds and large institutions have $99.3M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 3 closing their positions.
657% more call options, than puts
Call options by funds: $106K | Put options by funds: $14K
400% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 3
238% more capital invested
Capital invested by funds: $29.4M → $99.3M (+$69.9M)
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
46% more funds holding
Funds holding: 26 → 38 (+12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.86M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$3.51M |
| 3 |
BlackRock
New York
|
+$2.23M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.07M |
| 5 |
Two Sigma Advisers
New York
|
+$1.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$316K |
| 2 |
TI
Telemetry Investments
New York
|
-$310K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$246K |
| 4 |
Jane Street
New York
|
-$193K |
| 5 |
LC
Lindbrook Capital
Calabasas,
California
|
-$52K |
TCON Hedge Fund Activity: Q4 2020 in Review
38 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q4 2020, worth a combined $99.3M — up 238% from $29.4M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TCON positions and 3 closed out — a net gain of 12 holders — while 12 added to existing stakes and 4 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $3.86M. The largest seller was Virtu Financial, exiting entirely with an estimated $316K sold.
- 38 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q4 2020, up from 26 in Q3 2020.
- Funds reported $99.3M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q4 2020, up 238% quarter-over-quarter.
- 15 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 3 closed out, a net change of +12 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was Ikarian Capital, an estimated $3.86M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was Virtu Financial, an estimated $316K sold.
Based on aggregated 13F filings for Q4 2020.